SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
Medpage Today on MSN3d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...
Recent funding rounds in the digital health arena feature digital pathology startup Aignostics, remote care specialists TCC, ...
Boehringer Ingelheim has been awarded a multi-year contract to continue to provide antigen and vaccine supply capability as ...
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...
Today, the New Civil Liberties Alliance filed an amicus curiae brief with the U.S. Court of Appeals for the Second Circuit in Boehringer Ingelheim Pharmaceuticals v. Department of Health & Human ...
No. 49 / 2024 Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a solid financial ...
Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...
Junior Professor Johannes Walker, University of Göttingen, has been awarded an Exploration Grant from the Boehringer Ingelheim Foundation. Walker teaches and carries out research at the Institute for ...
Kikuchi–Fujimoto disease (KFD), histiocytic necrotising lymphadenitis, is a benign and self-limiting disease characterised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback